Reimportation Is "Phony" Issue, Waxman Says, But Driven By Real Pricing Problems
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimportation is not the solution to high U.S. drug prices, Rep. Henry Waxman (D-Calif.) said
You may also be interested in...
Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman
CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.
Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman
CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.
Reimportation Law Unlikely This Year Despite Democratic Pressure
Senate Majority Leader Frist says he does not expect to fit Rx import language into the schedule during the session’s remaining days. The Senate Health Committee has no plans to markup a bill.